Revvity Stock Surges 10% After Q3 2026 Earnings and Revenue Top Consensus Estimates

Revvity Inc. shares jumped roughly 10.2% in pre-market trading on November 3, 2026, after the life sciences and diagnostics company reported third-quarter results that beat Wall Street expectations on both the top and bottom lines. Consensus estimates heading into the report called for revenue of approximately $700.9 million and adjusted earnings per share of $1.29.

The company filed an 8-K with its Q3 results on November 3, and the beat was broad enough to make Revvity one of the standout pre-market movers that morning, appearing alongside names such as Shopify, Zebra Technologies, and Apple in morning mover roundups. By the close of regular trading, MarketWatch noted that Revvity stock had outperformed its competitors on what was described as a strong trading day for the name.

The Q3 report follows a trajectory of sequential revenue growth for Revvity in 2026: the company posted $711 million in Q1 and $730 million in Q2, with Q2 adjusted EPS of $1.41. Full-year 2026 guidance initiated earlier called for total revenue of $2.96 billion to $2.99 billion and adjusted EPS of $5.35 to $5.45, with organic growth of 2-3%.